Menu
Not yet recruiting NCT05705362

Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion

No phase Interventional Coronary Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Simple Crossover, Side branch opening.
Who it may be relevant to
Registry conditions: Coronary Artery Disease. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Randomized Controlled Trial of Simple CROSSsover Versus Side Branch Opening on Clinical Outcomes in Patients With Non-Left Main BIfurcation LeSion (CROSS-COBIS)

Overview

Hypothesis: Simple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion. A total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.

Detailed description

Despite advances in stenting techniques and devices, percutaneous coronary intervention (PCI) for bifurcation lesions remains one of the most challenging and complex procedures. Current guidelines recommend 1-stenting with provisional side branch (SB) approach should be an initial treatment strategy for the bifurcation lesions, based on the previous results of several randomized trials. However, the standardization of the provisional strategy is limited. In particular, there is a recommendation on the treatment technique for SB when SB intervention is required, but It has not been decided in which cases SB treatment is necessary, in the latest European Bifurcation Club (EBC) consensus document.16 In previous studies, the criteria for performing SB opening after MV stent intervention in the 1-stenting with provisional SB approach were varied. In the DK-CUSH II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) or CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) trials, SB intervention was performed when the SB diameter stenosis more than 50%, grade B or higher dissection, or blood flow disturbance (TIMI flow 2 or less) after MV stent insertion. On the other hand, in the Nordic trial, the authors applied strict criteria for SB intervention after MV stent insertion (TIMI flow 2 or less only). Furthermore, there have been conflicting results regarding the clinical and angiographic outcomes of the jailed SB opening strategy after the main vessel (MV) stenting, compared with the simple crossover strategy for non-left main bifurcation lesion.

On this background, this trial aims to compare the clinical outcomes between simple crossover and side branch opening strategies in patients with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.

Interventions

  • Procedure Simple Crossover
    Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
  • Procedure Side branch opening
    According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.

Primary outcome measures

  • Target-lesion failure [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
Secondary outcome measures (12)
  • All-cause death [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Cardiac death [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Myocardial infarction [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Target-vessel myocardial infarction [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Target-lesion revascularization [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Target-vessel revascularization [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Any revascularization [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Stent thrombosis [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Bleeding [Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)]
  • Total procedure time [Time frame: at 1 day]
  • Total amount of contrast use [Time frame: at 1 day]
  • Incidence of contrast induced nephropathy [Time frame: 72 hours after the index procedure]

Eligibility criteria

Inclusion criteria

  • (1) Subject must be at least 19 years of age
  • (2) Patients with non-left main bifurcation lesion (SB diameter ≥2.3 mm)
  • (3) Target lesions amenable for 1-stenting with provisional SB approach by operators' decision
  • (4) Angiographically compromised SB (visual SB stenosis ≥50%) after provisional MV stenting

Exclusion criteria

  • (1) Target lesions requiring elective 2-stenting technique by operators' decision (Observation Group 1)\*
  • (2) Patients who inevitably require SB intervention after MV stenting, as follows. (Observation Group 2)\*
  • Reduced SB TIMI flow (≤2) after MV stenting
  • SB dissection after MV stenting (≥ Type C)
  • (3) Patients without SB compromise after MV stenting (visually SB stenosis <50%) (Observation Group 3)\*
  • (4) Cardiogenic shock (Killip class IV) at presentation
  • (5) Patients with significant valvular heart disease or severe left ventricular systolic dysfunction (ejection fraction <35%)
  • (6) Pregnancy or breast feeding
  • (7) Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • (8) Unwillingness or inability to comply with the procedures described in this protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05705362 · CROSS-COBIS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗